Pancreatic cancer: Advances and challenges
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
efforts have largely defined major genetic factors driving PDAC pathogenesis and …
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE …
LJ Padrón, DM Maurer, MH O'Hara, EM O'Reilly… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
Targeting STAT3 in cancer immunotherapy
S Zou, Q Tong, B Liu, W Huang, Y Tian, X Fu - Molecular cancer, 2020 - Springer
As a point of convergence for numerous oncogenic signaling pathways, signal transducer
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
and activator of transcription 3 (STAT3) is central in regulating the anti-tumor immune …
Pancreatic cancer
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …
[HTML][HTML] Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer
Aerobic exercise is associated with decreased cancer incidence and cancer-associated
mortality. However, little is known about the effects of exercise on pancreatic ductal …
mortality. However, little is known about the effects of exercise on pancreatic ductal …
RAS-targeted therapies: is the undruggable drugged?
AR Moore, SC Rosenberg, F McCormick… - Nature reviews Drug …, 2020 - nature.com
Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
AR Parikh, A Szabolcs, JN Allen, JW Clark, JY Wo… - Nature cancer, 2021 - nature.com
Overcoming intrinsic resistance to immune checkpoint blockade for microsatellite stable
(MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains …
(MSS) colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) remains …
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I
K Yamamoto, A Venida, J Yano, DE Biancur… - Nature, 2020 - nature.com
Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion
include impaired antigen presentation caused by mutations or loss of heterozygosity of the …
include impaired antigen presentation caused by mutations or loss of heterozygosity of the …